

---

## OHD\_NewsletterJuly24 - Hi Maria Paola, Join Us in Shaping our Action's Future: Contribute to Our Stakeholder Analysis Initiative

1 messaggio

---

**OneHealthDrugs COST Action** <onehealthdrugs.events@gmail.com>

1 luglio 2024 alle ore 14:14

Rispondi a: onehealthdrugs.events@gmail.com

A: mariapaola.costi@unimore.it

If you can't see this newsletter properly, please click [here](#)



**STAKEHOLDER**  
*Analysis*



---

[Action Site](#) [COST Action](#) [LinkedIn](#) [YouTube](#) [X-Twitter](#)

### In this edition ...

- Contribute to OHD **Stakeholder Analysis Initiative**
- OHD **Upcoming Events**

- **OHD Events outcomes: Reporting from Paul Ehrlich Euro-PhD Network & OneHealthdrugs COST Action MEETING 17-19 June 2024**
- **Experience of Young researcher in COST Action CA21111OHD Action project related meetings**
- **OHD SciComm activity**
- **OHD available positions**

---

## Message from the Action Chair

---

July 1<sup>st</sup>, 2024

Dear Valued OneHealthDrugs Members,

Happy July and welcome to the latest edition of our newsletter! As we bask in the warmth of summer, we are thrilled to announce an exciting new initiative: a comprehensive **Stakeholder Analysis**. This effort is fundamental to enhancing our project's impact and success, and we need your invaluable insights and expertise to make it happen.

We are excited to announce the commencement of our stakeholder analysis during the hybrid meeting in Oxford with a dedicated session that will focus specifically on this critical aspect of our project.

We will begin by introducing the framework for our stakeholder analysis which will be conducted by Theo Zacharis. Following this introduction, our efforts will be divided into three primary tasks at this initial stage:

- **Identifying Stakeholder Groups & Individuals/Entities:** We will start by identifying broad stakeholder groups before suggesting specific individuals and entities for each group. This step is crucial for ensuring that we encompass all relevant perspectives and interests.



- **Selecting Appropriate Stakeholder Analysis Tools:** Once we have identified the stakeholder groups, we will select the most suitable Stakeholder Analysis tools. These tools will help us determine which stakeholders to reach and engage with, based on their influence and interest in our project.

## Stakeholders Analysis Tools

**Stakeholder Analysis Matrix:** A table used to evaluate stakeholders based on various criteria such as interest, influence, power, and support. This helps in **prioritizing** stakeholder engagement strategies.

**Power-Interest Grid:** This tool plots stakeholders on a grid based on **their level of interest** in the project and their power to influence it. It helps in identifying which stakeholders need **more attention** and which can be monitored with less frequent communication.

**SWOT Analysis:** Sometimes adapted for stakeholder analysis by assessing the **Strengths, Weaknesses, Opportunities, and Threats** that stakeholders bring to a project.

**Salience Model:** This model classifies stakeholders based on three attributes: **power, legitimacy, and urgency**. It helps in understanding who should be given priority based on their attributes' combination.

**Influence-Impact Grid:** Similar to the Power-Interest grid, this tool helps in assessing stakeholders based on their **influence** over the project and the **impact** the project has on them.

**Stakeholder Engagement Assessment Matrix:** This matrix helps in determining the **current level of engagement** of each stakeholder and the **desired level of engagement** to ensure project success.

OHD Stakeholders Analysis Theo Zacharis - 03 July 2024

- **Developing a Draft Action Plan:** Finally, we will draft an action plan that includes clear milestones and timelines. This plan will guide our engagement efforts and ensure we have a structured approach to stakeholder management.



These steps will be specifically applied to two key deliverables:

1. **White Paper on the Environmental Impact of Antiparasitic Drugs:** This document will raise awareness about the environmental consequences of these drugs and provide recommendations for mitigating their negative impacts.
2. **Guidelines for the Development of Low Environmental Impact Antiparasitic Drugs:** These guidelines will offer a roadmap for creating environmentally friendly antiparasitic drugs, addressing criteria, best practices, and a regulatory framework.

As we approach the Oxford meeting (July 3-5), **we encourage all members to come prepared with suggestions for stakeholder groups and potential individuals.** Please take some time to consider and propose relevant stakeholders who can significantly contribute to these efforts.

Your participation in identifying and engaging with key stakeholders in the upcoming session will help us build stronger collaborations, anticipate and address challenges, and ensure that our project aligns seamlessly with stakeholder expectations. Together, we can create a more inclusive and responsive project environment.


Wishing you a joyful and productive July!

by [Maria-Paola Costi](#), Action Chair





Workshop on Stakeholders Analysis - Phase I





## Help us shape the OHD Network: Identify Key Stakeholders

This survey is designed to gather insights from OHD members on identifying key stakeholders for the One Health Drugs Dissemination & Exploitation. Your valuable input will help us understand our network better and facilitate more effective collaborations.

[Start](#)

---

### OHD Works

---

#### Upcoming Events

- WG1 WG2 Conference "Structural and functional drug discovery for vector-borne diseases". Oxford (UK) 3-5 July 2024
- WG4 meeting 10th July 2024 14:00-15:00 pm CET (VIRTUAL)
- WG6 meeting 19th July 2024 14:30-15:30 pm CET (VIRTUAL)
- WG5 meeting 24th July 2024 15:00-17:00 pm CET (VIRTUAL)
- HG4 meeting 25th July 2024 17:00-18:00 pm CET (VIRTUAL)



---

**Said Business School, Oxford, UK, 3-5 July 2024**



## OHD Events outcomes

**Reporting from Paul Ehrlich Euro-PhD Network  
& OneHealthdrugs COST Action MEETING 17-19  
June 2024**

**Elisa Uliassi**

**HG4 Horizontal Group Leader**

University of Bologna, Italy



Dear OneHealthdrugs colleagues and young researcher innovators (YRI),

the **Paul Ehrlich Euro-PhD Network & OneHealthdrugs COST Action MEETING** took place in Rome (June 17-19,2024) and has been a great opportunity for all young investigators to share and discuss their research and to network with all attendees. The Paul Ehrlich Euro-PhD Network is the largest EU PhD network with 65 Universities from 23 Countries whose final aim is to provide an in-depth research training and mobility of PhD students in the area of Medicinal Chemistry at European level. Thus, the dedicated OneHealthdrugs Workshop "One Health approach to tackle neglected infectious diseases challenges " has provided the ideal international platform for YRI to present their research work in the field of neglected infectious diseases: Trypanosomiasis, Leishmaniosis, Schistosomiasis, Malaria and others in the field of medicinal

chemistry/green chemistry and ecotoxicology.

The meeting brought together 130 participants from 20 countries. The program included 3 plenary lectures and 1 invited lecture by leading scientists from academia as well as 31 oral communications by young and senior investigators. Moreover, 34 posters were presented in highly interactive poster sessions and flash presentations.

The OneHealth*drugs* Workshop on DAY 2 (June 18th) has been chaired by Profs Daniela Secci and Paola Costi and opened by the inspiring and amazing lecture by Prof. Rohini Roopnarine. Rohini Roopnarine is Professor at the School of Veterinary Medicine, and adjunct professor Dept. of Public Health & Preventive Medicine, School of Medicine, at St. George's University and CA21111 member. Her research focuses in Interprofessional Education and One Health Education. Her presentation has highlighted on the importance of the One Health principles/education/awareness in the field of VBPD, with particular emphasis on the medicinal chemistry aspects. Then, Dr Elisa Uliassi presented the Young Researcher Innovators (YRI < 40 years) Horizontal Group (HG) 4 within COST Action CA21111 – OneHealth*drugs*. Her presentation introduced the HG4 aims, activities and events with the objective to stimulate YRI research, training and networking activities across all areas of VBPD, by creating new knowledge and technologies according to the *One Health goals*. HG4 is also committed to raise awareness and to make VPBD research more environment conscious.

Following, 13 flash presentations delivered by YRI working in the field of VBPD have brilliantly showed the different med chem approaches pursued against VBPD. The workshop has been closed by Prof Stefano Alcaro with an excellent presentation on The Chemotheca – a computational facility containing virtual compounds developed within MuTaLig COST ACTION CA15135 -, as a promising networking tool for collecting also hits and leads developed within the OneHealth*drugs* Cost Action.

We have emphasized the critical need of broadening the range of drugs to combat VPBDs and the imperative to significantly alter the existing approaches to drug discovery and development. Medicinal chemistry/green chemistry can be integrated with ecotoxicology perspective thus allowing the design of more environmentally friendly hits and leads for VBPD. This approach increases the chances to reduce their broad toxicity to the living organisms and environment.

In this sense, we hope to have contributed to strengthening YRI's foundation in OHD topics and to make their involvement into our OHD Action even higher. By joining the



HG4, YRI will have the opportunity to meet and network with other young researchers as well as with more senior researchers. The best way to do this is to become CA21111 member, join our events and activities.

Looking at the future, we are focused on establishing a new avenue to innovative therapeutics for VBPD according to the One Health principles.

I would like to express my gratitude to all organizers, speakers and participants for their invaluable contributions and active participation in this enlightening meeting. A special thank goes to the Local Organizing Committee, and in particular to Prof Daniela Secci. Our sincere thanks to Prof Rohini Roopnarine who was fundamental in the inauguration of this event. We thank Professor Maria Paola Costi for her endless enthusiasm and commitment to the OneHealth*drugs* COST Action.

Once again, we thank everyone who made this event possible.

With best regards

Elisa Uliassi

---

### News from the Training school in Naples **Natural products in antiparasitic drug discovery: experimental and computational approaches**

Experience of Young researcher in **COST Action CA21111**-One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealth*drugs*).

**Hafidh AKKARI**

National Veterinary School of Sidithabet, Tunisia

**Working Groups:** WG1, WG3, WG4



---

#### **Background:**

Viewed globally, Vector-Borne parasitic diseases pose an increasing threat to human health and welfare and continue as a cause of suffering for many millions of people in both tropical and subtropical zones of the world. However, the available therapeutic tools

for the treatment of most parasitic diseases are extremely limited. Many of them were developed in the first part of past century and are not without risk. The development of resistant parasites to many of the available drugs is also responsible for the depressing picture of disease persistence and death. Drug resistance is spreading faster than ever, new drugs are not being developed quickly enough and potential vaccines have so far not fulfilled expectations in field trials. Although alternative antiparasitic drugs are urgently needed, the response to this crisis is inadequate. The field suffers not so much from a lack of promising scientific approaches, but a lack of funding and commitment from both public sector agencies and the pharmaceutical industry to convert these approaches into new drugs.

OneHealth*drugs* project summarises the medical need for a number of vector borne diseases in terms of their treatment and their limitations, highlighting desirable product profiles for current and future drug discovery and development including ecotoxicity. It further investigates the reasons for the lack of industrial activity in these diseases and identifies the key elements of any new mechanisms initiated to ensure the sustainable enhancement of neglected disease drug in the future. In addition, the network WG members reinforced the urgency to extend the portfolio of drugs used in the fight against VBDs and absolute need to consider a change of the current paradigms of drug discovery and development, towards a multidisciplinary approach that takes into account innovation, drug efficiency and safety and environmental protection.

### **Why did you join the OneHealthdrugs network?**

As a researcher with a solid background in VBPD, the opportunity to join the OneHealth*drugs* COST Action (CA21111) was extremely interesting and very timely in my professional career, as I was preparing to defend my HDR thesis. My thesis focused on the use of medicinal plants against vector-borne diseases: Evaluation of *in vitro* leishmanicidal activity of *the* Chamomile essential oil.

With my HDR research studies coming to an end, participation within the network seemed a great opportunity to broaden my knowledge and expertise, building on my post-doctoral studies. The discovery of new drugs for Human and Animal infections under the concept of OneHealth*drugs* has never been explored at local levels in Tunisia. Being part of the network was a good opportunity for me to work with other experts in the network to develop new methodological approaches to explore this, and also to help build up skills in translating knowledge to research in my laboratory and public health professionals back home. I will also continue this spirit of innovation and scientific research to establish research collaborations for innovation in drug development and fuel a more sustainable future for all who rely on medicines to combat vector-borne parasitic diseases.

### Tell us about your experience within the burden-EU network so far?

I was fortunate to be member of the network to participate in a series of online and in-person conferences. The aim of these meetings was to familiarise with the concept of OneHealth*drugs*. This led to a successful publication in Experimental parasitology as well as poster and oral presentations. Am also honored by my participation in two training schools where I had basic knowledge on innovation in the field of drugs discovery. Other benefits of being an active member of the network has been the opportunity to connect with other small states members, where together we have been developing further collaborative research efforts.


## OHD SciComm activity

We invite you to actively support our Action's SciComm plan, which is crucial for amplifying our collective impact and enhancing your visibility within the scientific community. Join our LinkedIn group and subscribe to our YouTube channel to post your work, engage in discussions, and share our content. Your participation is vital in expanding our reach and elevating your professional presence in the field.



### Subscribe to our YouTube channel


### Join the OneHealthdrugs LinkedIn Group!




**OneHealthdrugs**  
@OneHealthdrugs · 12 subscribers · 8 videos  
[More about this channel](#)  
[Customise channel](#) [Manage videos](#)

[Home](#) [Videos](#) [Playlists](#) [Q](#)


**Uploads** ▶ [Play all](#)




**OHD Upcoming Events April 24**  
36 views · 1 month ago




**Help us shape the OHD Network: Identify Key...**  
8 views · 2 months ago



**OneHealthDrugs celebrates Women In STEM**  
141 views · 4 months ago



**Season's Greetings from the OneHealthdrugs Community**  
192 views · 5 months ago



**OHD's Young Researchers and Innovators (YRI) expl...**  
83 views · 5 months ago

### Follow us on X (Twitter)



visit our website



About us   Structure   Working Area   Events (Calendar 2024)   News   Dissemination   STSM   Contacts   [Join us](#)

Login

Women in STEM   NTD Day 30 January 2024

and don't forget to complete our survey, if you haven't done it so far.



## OHD available positions

- WG6 Leadership
- WG4-Vice leader



- Young Researcher and Innovators



I wish to share with the OHD Community

## Give us your valuable feedback

We will be pleased to answer any questions you may have or consider suggestions for improving our Community.

Please email us at [onehealthdrugs.events@gmail.com](mailto:onehealthdrugs.events@gmail.com)

Contact us if you have any questions,  
suggestions or you wish to share your news



CA21111 - One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthdrugs)

[Unsubscribe me](#) | [Change my information](#)